Sanofi (SNYNF) Cash from Discontinued Operations (2019 - 2025)
Sanofi (SNYNF) posted Cash from Discontinued Operations of 216512093.73 for Q4 2025, down 199.04% sequentially from 218613302.08 in Q3 2025.
Sanofi (SNYNF) Cash from Discontinued Operations (2019 - 2025) Analysis & Trends
Sanofi (SNYNF) has 7 years of Cash from Discontinued Operations data on file, last reported at 216512093.73 in Q4 2025.
- Quarterly Cash from Discontinued Operations changed N/A year-over-year to 216512093.73 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 200095708.73 (changed N/A YoY) and the FY2025 annual result came in at 220004224.28, down 56.57% from the prior year.
- Cash from Discontinued Operations declined to 216512093.73 in Q4 2025 per SNYNF's latest filing, from 218613302.08 in the prior quarter.
- The five-year high for Cash from Discontinued Operations was 12036862347.84 in Q4 2021, with the low at 216512093.73 in Q4 2025.
- Average Cash from Discontinued Operations over 5 years is 3683393063.94, with a median of 194598621.31 recorded in 2025.
- Year-over-year, Cash from Discontinued Operations jumped 36.1% in 2021 and sank 93.69% in 2025.
- Sanofi's Cash from Discontinued Operations stood at 12036862347.84 in 2021, then declined by 10.78% to 10739123767.12 in 2022, then declined by 7.11% to 9975038896.17 in 2023, then tumbled by 99.46% to 53844378.81 in 2024, then sank by 502.11% to 216512093.73 in 2025.
- Business Quant data shows SNYNF's Cash from Discontinued Operations at 216512093.73 in Q4 2025, 218613302.08 in Q3 2025, and 3395879.06 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 3.36 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Sanofi | - | - | 9.49 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -216.51 Mn |
| Dec 31, 2025 | -216.51 Mn |
| Sep 30, 2025 | 218.61 Mn |
| Sep 30, 2025 | 218.61 Mn |
| Jun 30, 2025 | 3.40 Mn |
| Jun 30, 2025 | 3.40 Mn |
| Mar 31, 2025 | 194.60 Mn |
| Mar 31, 2025 | 194.60 Mn |
| Jun 30, 2024 | 53.84 Mn |
| Jun 30, 2024 | 53.84 Mn |
| Mar 31, 2024 | 145.57 Mn |
| Mar 31, 2024 | 145.57 Mn |
| Dec 31, 2023 | 9.98 Bn |
| Dec 31, 2023 | 9.98 Bn |
| Dec 31, 2022 | 10.74 Bn |
| Dec 31, 2022 | 10.74 Bn |
| Dec 31, 2021 | 12.04 Bn |
| Dec 31, 2021 | 12.04 Bn |
| Dec 31, 2020 | 8.84 Bn |
| Dec 31, 2020 | 8.84 Bn |